Extranodal diffuse large B-cell lymphoma presenting with extensive organ involvement

被引:0
作者
Kim, Kailyn [1 ]
Ziyeh, Sharvina [2 ]
Kim, Phyllis [2 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Med Ctr Ol View, Sylmar, CA USA
[2] Univ Calif Los Angeles, Med Ctr Ol View, Dept Hematol Oncol, Sylmar, CA 91342 USA
关键词
Chemotherapy; Oncology; Haematology (incl blood transfusion); Malignant and Benign haematology; PROGRESSION-FREE SURVIVAL; NON-HODGKINS-LYMPHOMAS; DOUBLE-HIT LYMPHOMAS; RITUXIMAB ERA; SINGLE-ARM; SITES; MULTICENTER; EXPRESSION; OUTCOMES; MYC;
D O I
10.1136/bcr-2023-257416
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Extranodal involvement in diffuse large B-cell lymphoma (DLBCL) is defined as disease outside of the lymph nodes and occurs in up to one-third of patients, though multiorgan extranodal involvement is rare. Here, we describe a case of a patient presenting with widely metastatic lesions, including involvement of the lung, parotid gland, breast, pancreas, femur and multiple soft tissue masses, with initial concern for primary breast malignancy. Breast pathology and imaging were consistent with triple-expressor, double-hit stage IV high-grade B-cell lymphoma with extensive extranodal involvement. Extranodal involvement is a poor prognostic factor associated with high rates of treatment failure, and novel therapies targeting CD19 are currently being studied for relapsed and refractory DLBCL. Extranodal disease is a complex entity that can involve virtually any organ system and should be considered for new presentations of malignancy.
引用
收藏
页数:4
相关论文
共 33 条
  • [1] Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
    Bobillo, Sabela
    Joffe, Erel
    Lavery, Jessica A.
    Sermer, David
    Ghione, Paola
    Noy, Ariela
    Caron, Philip C.
    Hamilton, Audrey
    Hamlin, Paul A.
    Horwitz, Steven M.
    Kumar, Anita
    Matasar, Matthew J.
    Moskowitz, Alison
    Owens, Colette N.
    Palomba, M. Lia
    Batlevi, Connie L.
    Straus, David
    von Keudell, Gottfried
    Zelenetz, Andrew D.
    Yahalom, Joachim
    Dogan, Ahmet
    Seshan, Venkatraman E.
    Younes, Anas
    [J]. BLOOD, 2021, 137 (01) : 39 - 48
  • [2] Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the Surveillance, Epidemiology and End Results database
    Castillo, Jorge J.
    Winer, Eric S.
    Olszewski, Adam J.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (03) : 310 - 314
  • [3] Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma
    Chen, Andy I.
    Leonard, Jessica T.
    Okada, Craig Y.
    Gay, Nathan D.
    Chansky, Kari
    Fan, Guang
    Dunlap, Jennifer B.
    Raess, Philipp W.
    Braziel, Rita M.
    Stentz, Alex
    Maziarz, Richard T.
    [J]. LEUKEMIA & LYMPHOMA, 2018, 59 (08) : 1884 - 1889
  • [4] Extensive Extranodal Involvement of Rare Sites in Non Hodgkin's Lymphoma Detected on 18F- FDG PET-CT: A Case Report
    Dhull V.S.
    Sharma P.
    Singla S.
    Faizi N.A.
    Thulkar S.
    Bal C.
    Kumar R.
    [J]. Nuclear Medicine and Molecular Imaging, 2013, 47 (2) : 125 - 129
  • [5] Duell J, 2021, HAEMATOLOGICA, V106, P2417, DOI [10.3324/haematol.2020.275958, 10.3324/haematol.2021.279802]
  • [6] Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study
    Dunleavy, Kieron
    Fanale, Michelle A.
    Abramson, Jeremy S.
    Noy, Ariela
    Caimi, Paolo Fabrizio
    Pittaluga, Stefania
    Parekh, Samir
    Lacasce, Ann
    Hayslip, John W.
    Jagadeesh, Deepa
    Nagpal, Sunil
    Lechowicz, Mary Jo
    Gaur, Rakesh
    Lucas, Andrea
    Melani, Christopher
    Roschewski, Mark
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Kahl, Brad
    Friedberg, Jonathan W.
    Little, Richard F.
    Bartlett, Nancy L.
    Wilson, Wyndham H.
    [J]. LANCET HAEMATOLOGY, 2018, 5 (12): : E609 - E617
  • [7] The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy
    El-Galaly, Tarec Christoffer
    Villa, Diego
    Michaelsen, Thomas Yssing
    Hutchings, Martin
    Mikhaeel, Nabegh George
    Savage, Kerry J.
    Sehn, Laurie H.
    Barrington, Sally
    Hansen, Jakob W.
    Smith, Daniel
    Rady, Kirsty
    Mylam, Karen J.
    Larsen, Thomas S.
    Holmberg, Staffan
    Juul, Maja B.
    Cordua, Sabrina
    Clausen, Michael R.
    Jensen, Kristina B.
    Johnsen, Hans E.
    Seymour, John F.
    Connors, Joseph M.
    Brown, Peter de Nully
    Bogsted, Martin
    Cheah, Chan Y.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 75 : 195 - 203
  • [8] Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma
    El-Galaly, Tarec Christoffer
    Villa, Diego
    Alzahrani, Musa
    Hansen, Jakob Werner
    Sehn, Laurie H.
    Wilson, Don
    Brown, Peter de Nully
    Loft, Annika
    Iyer, Victor
    Johnsen, Hans Erik
    Savage, Kerry J.
    Connors, Joseph M.
    Hutchings, Martin
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (11) : 1041 - 1046
  • [9] Eyre TA, 2022, LANCET ONCOL, V23, pE416, DOI 10.1016/S1470-2045(22)00371-0
  • [10] Real-World Data (RWD) on the 3-Year Follow-Up Outcomes of Different CNS Prophylaxis Strategies Across CNS-IPI Risk Groups in Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
    Faqah, Anadil
    Asif, Summaiya
    Goksu, Suleyman Yasin
    Sheikh, Hassan S.
    [J]. JCO GLOBAL ONCOLOGY, 2021, 7 : 486 - 494